HematologyNews.net

Hematology Xagena

Chronic ophthalmological complications of SCD include proliferative sickle retinopathy ( PSR ) and vitreous hemorrhage. They occur in up to 50% of individuals with SCD, and are found more frequently ...


The FDA ( Food and Drug Administration ) has approved a Supplemental New Drug Application ( sNDA ) for Eliquis ( Apixaban ) for the treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( P ...


Chronic kidney disease ( CKD ) is defined as either having a glomerular filtration rate ( GFR ) of less than 60 mL/min/1.73 mL for more than 3 months with or without kidney damage or having evidence o ...


Data from FIRST, an open-label phase III randomized study of continuous Lenalidomide ( Revlimid ) in combination with Dexamethasone in patients newly diagnosed with multiple myeloma ( NDMM ) who are n ...


Pulmonary hypertension ( PH ) is defined as an elevation of the resting mean pulmonary arterial pressure ( greater than or equal to 25 mmHg ) as determined by right heart catheterization ( RHC ). Th ...


Leg ulcers are a common complication of sickle cell disease ( SCD ) in general and sickle-cell anaemia ( SCA ) in particular. Leg ulceration was reported in all of the first four people with sickle ce ...


Patients with chronic lymphoid leukemia ( CLL ) or small lymphocytic lymphoma ( SLL ) who experience short response duration or adverse cytogenetics have poor outcomes. Researchers have evaluated th ...


Avascular necrosis ( AVN, also known as aseptic necrosis, osteonecrosis, or ischemic necrosis ) is bone death due to compromised blood supply. Necrosis can occur when capillaries are occluded by sic ...


The Food and Drug Administration ( FDA ) has approved a supplemental New Drug Application ( sNDA ) for the once-daily use of Eltrombopag in patients with severe aplastic anaemia who have had an insuff ...


In sickle cell disease ( SCD ), pain is considered chronic if it lasts more than 3 months. People with sickle cell disease experience both nociceptive and neuropathic pain. Nociceptive pain is a hallm ...


The Pharmacovigilance Risk Assessment Committee ( PRAC ) of the European Medicines Agency ( EMA ) has concluded its review of Iclusig ( Ponatinib ) under the Article 20 referral procedure and has reco ...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia ( AML ) aged 65 or older and ineligible f ...


Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma ( DLBCL ) given a regimen of Rituximab ( MabThera, Rituxan ), Cyclophosphamide ( Endoxan ), Doxorubicin ( Adriamycin ), Vincr ...


Intravenous Rituximab ( MabThera, Rituxan ) is a mainstay of treatment for follicular lymphoma. A subcutaneous formulation that achieves equivalent Rituximab serum concentrations might improve conveni ...


Acute graft-versus-host disease ( GVHD ) remains a barrier to more widespread application of allogeneic haemopoietic stem-cell transplantation. Vorinostat ( Zolinza ) is an inhibitor of histone deac ...


Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune checkpoints in the tumour microenvironment. These checkpoints migh ...


Chemoimmunotherapy has led to improved numbers of patients achieving disease response, and longer overall survival in young patients with chronic lymphocytic leukaemia; however, its application in eld ...


Lenalidomide ( Revlimid ) has been linked to second primary malignancies in myeloma. Researchers have aimed to pool and analyse available data to compare the incidence of second primary malignancies i ...


Beta-thalassemias are characterized by ineffective red blood cell ( RBC ) production, leading to anemia, iron overload, and organ failure. As current treatment options for beta-thalassemia are limited ...


In acute lymphoblastic leukemia ( ALL ) response to therapy is usually measured by microscopic analysis of the bone marrow. The detection level for leukemic cells by this method is 5%. With molecular ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati